Latest Top Picks

(A Top Pick Jul 05/18, Up 28%) Anthem is in managed care in health care, dominant in Blue Cross/Blue Shield in 13 U.S. states. It's recovered well since April when the Medicare for all calls were coming from Washington. Still likes Anthem and it continues to do well. It consistently delivers.

(A Top Pick Jul 05/18, Up 3%) One of the world's largest biotech companies. They have 3-4 blockbuster drugs in the pipeline in phase 1 & 2. It's an under-owned stock. Enbrel, their largest-selling drug, is undergoing a parent review. If Amgen wins--which he thinks will happen--then there'll be a 12% stock boost; if not, it will fall 12%. Either way, after this review, Amgen is still worth buying.

(A Top Pick Jul 05/18, Up 37%) It's been his top pick for three years. They continue to execute, like their immunotherapy drug. Trades at only 15x earnings with a good rate of return. The market is focused on their Keytruda therapy which merck is executing well.

A diversified drugmaker that generates consistent returns. Patent declines are offset by a deep pipeline of new drugs from acquisitions. Also boast and organic R&D. MRK pays an attractive yield and has a decent balance sheet. Positive developments continue from Keytruda, an immuno-oncology therapy. MRK trades at 15x earnings. (Analysts’ price target is $91.73)

A higher-risk/return play. This biotech has several core products generating good free cash flow. They’re partnering with Sanofi on Dupixent to treatment severe atopic dermatitis and potentially severe asthma. They also have another drug to treat specific eye diseases. REGN boasts various late-stage drug trials.
Regeneron is a new Top Pick for us, driven by the valuation having compressed significantly on concerns over U.S. Medicare Part B drug pricing policy proposals. We believe these are more than reflected in the current price.Their dermatitis drug is getting traction. This stock has been beat up for the wrong reasons. This (Analysts’ price target is $389.38)

0

0

0

0

0

Your Reaction

Stock Opinions by Paul MacDonald - Stockchase Experts

The slight sell-off today was due to the summer doldrums during a big earnings week. People are hesitant despite all the market noise. But investors are jittery because we are late-market. This earnings season is important, because it sets the tone for the end of the year. Keep your pencil sharp. The heat is off the health sector a bit following rhetoric from Washington against the US healthcare companies last spring. A result of that was a sell-off in health stocks, but earnings reports are coming in robust. He is more confident about this sector now than just a few months ago. It looks unlikely that Washington will push through new health care policies, like price transparency on TV ads. But expect continued volatility. You have to be in health care now given valuations, tech innovations, developing markets and aging demographics.

The slight sell-off today was due to the summer doldrums during a big earnings week. People are hesitant despite all the market noise. But investors are jittery because we are late-market. This earnings season is important, because it sets the tone for the end of the year. Keep your pencil sharp. The heat is off the health sector a bit following rhetoric from Washington against the US healthcare companies last spring. A result of that was a sell-off in health stocks, but earnings reports are coming in robust. He is more confident about this sector now than just a few months ago. It looks unlikely that Washington will push through new health care policies, like price transparency on TV ads. But expect continued volatility. You have to be in health care now given valuations, tech innovations, developing markets and aging demographics.

It's been painful as it consolidates for the past 18 months. They have a hepatitis franchise, an expensive drug, that came off patent. Gilead failed to reinvest those profits, too. Their HIV franichise is doing very well. They acquired some companies, which look promising. The CEO is doing a good job. They are trading 9.5x fowarding earnings. Great dividend yield and balance sheet.

It's been painful as it consolidates for the past 18 months. They have a hepatitis franchise, an expensive drug, that came off patent. Gilead failed to reinvest those profits, too. Their HIV franichise is doing very well. They acquired some companies, which look promising. The CEO is doing a good job. They are trading 9.5x fowarding earnings. Great dividend yield and balance sheet.

They're a UK medical technology company, 75% in hips and knees. They had hiccups a year ago in their wound management business, but have subsided. He has owned this. He doesn't own it now, because the options market isn't very liquid in the U.S. Also, Stryker is the leader in robotics, and SNN is only second or third, launching in 2021. SNN has similar growth to Stryker. Good to hold.

They're a UK medical technology company, 75% in hips and knees. They had hiccups a year ago in their wound management business, but have subsided. He has owned this. He doesn't own it now, because the options market isn't very liquid in the U.S. Also, Stryker is the leader in robotics, and SNN is only second or third, launching in 2021. SNN has similar growth to Stryker. Good to hold.

Abbvie has Humira, an $18-20 billion arthritis drug that will lose patent protection. ABBV bought Allergan under pressure to diversify--they needed to. They at 7.5x earnings with little growth after 2021. The Allergan purchase won't add much growth, but will lessen risk; Abbvie won't need to rely so much on Humira for revenues. The Allergan deal isn't done yet, but he likes it. Likes ABBV's dividend.

Abbvie has Humira, an $18-20 billion arthritis drug that will lose patent protection. ABBV bought Allergan under pressure to diversify--they needed to. They at 7.5x earnings with little growth after 2021. The Allergan purchase won't add much growth, but will lessen risk; Abbvie won't need to rely so much on Humira for revenues. The Allergan deal isn't done yet, but he likes it. Likes ABBV's dividend.

BMY was going down before their Celgene purchase, which was a good deal (he owned Celgene) at a bargain. BMY didn't do anything particularly wrong; their drugs are doing well. However, Merck is the dominant player in this space with better science, and so is his preferred pick. Better to hold a basket of health stocks though to lessen risk in holding individual health stocks--science keeps changing.

BMY was going down before their Celgene purchase, which was a good deal (he owned Celgene) at a bargain. BMY didn't do anything particularly wrong; their drugs are doing well. However, Merck is the dominant player in this space with better science, and so is his preferred pick. Better to hold a basket of health stocks though to lessen risk in holding individual health stocks--science keeps changing.

It's a machine that makes acquisitions which generate revenues worldwide. However, they lack growth and a presence in oncology though they recenly made an aquisition that can help growth. Expect modest growth, but limited downside too if a clinical trial fails. Good dividend and balance sheet. Good to hol.

It's a machine that makes acquisitions which generate revenues worldwide. However, they lack growth and a presence in oncology though they recenly made an aquisition that can help growth. Expect modest growth, but limited downside too if a clinical trial fails. Good dividend and balance sheet. Good to hol.

How many healthcare stocks should you hold in a portfolio? Worldwise, health care makes up 12-15% of the market, but only 3% on the TSX, and 70% of that is cannabis. Canada has limited choices in health care stocks. A portfolio should hold 10% health stocks, and 15% during volatility.

How many healthcare stocks should you hold in a portfolio? Worldwise, health care makes up 12-15% of the market, but only 3% on the TSX, and 70% of that is cannabis. Canada has limited choices in health care stocks. A portfolio should hold 10% health stocks, and 15% during volatility.

(A Top Pick Jul 05/18, Up 28%) Anthem is in managed care in health care, dominant in Blue Cross/Blue Shield in 13 U.S. states. It's recovered well since April when the Medicare for all calls were coming from Washington. Still likes Anthem and it continues to do well. It consistently delivers.

(A Top Pick Jul 05/18, Up 28%) Anthem is in managed care in health care, dominant in Blue Cross/Blue Shield in 13 U.S. states. It's recovered well since April when the Medicare for all calls were coming from Washington. Still likes Anthem and it continues to do well. It consistently delivers.

(A Top Pick Jul 05/18, Up 3%) One of the world's largest biotech companies. They have 3-4 blockbuster drugs in the pipeline in phase 1 & 2. It's an under-owned stock. Enbrel, their largest-selling drug, is undergoing a parent review. If Amgen wins--which he thinks will happen--then there'll be a 12% stock boost; if not, it will fall 12%. Either way, after this review, Amgen is still worth buying.

(A Top Pick Jul 05/18, Up 3%) One of the world's largest biotech companies. They have 3-4 blockbuster drugs in the pipeline in phase 1 & 2. It's an under-owned stock. Enbrel, their largest-selling drug, is undergoing a parent review. If Amgen wins--which he thinks will happen--then there'll be a 12% stock boost; if not, it will fall 12%. Either way, after this review, Amgen is still worth buying.

(A Top Pick Jul 05/18, Up 37%) It's been his top pick for three years. They continue to execute, like their immunotherapy drug. Trades at only 15x earnings with a good rate of return. The market is focused on their Keytruda therapy which merck is executing well.

(A Top Pick Jul 05/18, Up 37%) It's been his top pick for three years. They continue to execute, like their immunotherapy drug. Trades at only 15x earnings with a good rate of return. The market is focused on their Keytruda therapy which merck is executing well.

Since 2014, management has executed very good 7-9% organic EPS growth while compressing margins on the cost side. Last quarter, though, they had a hiccup with their Watchman device, but the market forgave them because of BSX's track record. Happy to own it. They report next week. If they miss, expect volatility.

Since 2014, management has executed very good 7-9% organic EPS growth while compressing margins on the cost side. Last quarter, though, they had a hiccup with their Watchman device, but the market forgave them because of BSX's track record. Happy to own it. They report next week. If they miss, expect volatility.

AZN has a very deep phase-3 pipeline of drugs being tested and tried. The growth won't kick in until 2021-3. He loves their dividend. They've been shedding assets to focus on less price-sensitive areas. Earnings are 16x, going down to 14x in 2020. This will be a lighter quarter, because they aren't selling as many assets, but he's happy to own this.

AZN has a very deep phase-3 pipeline of drugs being tested and tried. The growth won't kick in until 2021-3. He loves their dividend. They've been shedding assets to focus on less price-sensitive areas. Earnings are 16x, going down to 14x in 2020. This will be a lighter quarter, because they aren't selling as many assets, but he's happy to own this.

Comments

Stockchase, in its reporting on what has been discussed by individuals on business
television programs (in particular Business News Network), neither recommends nor
promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood
from the experts’ comments.
We are human and can make mistakes,
help us fix any errors. If you see something that you know is not right or if there is a
problem with the site, feel free to email us at :
hello@stockchase.com.